메뉴 건너뛰기




Volumn 7, Issue 4, 2015, Pages 286-303

Statistical Considerations on Subgroup Analysis in Clinical Trials

Author keywords

Bayesian subgroup analysis; Chance findings; Enrichment; Heterogeneity; Personalized medicine; Targeted and complementary subgroups

Indexed keywords

CLINICAL TRIAL; HUMAN; PERSONALIZED MEDICINE; POPULATION MODEL; RISK ASSESSMENT; STATISTICAL MODEL;

EID: 84950314815     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2015.1077726     Document Type: Article
Times cited : (58)

References (36)
  • 1
    • 61749083299 scopus 로고    scopus 로고
    • A Flexible Strategy for Testing Subgroups and Overall Population
    • M.Alosh,, and M.F.Huque, (2009), “A Flexible Strategy for Testing Subgroups and Overall Population,” Statistics in Medicine, 28, 3–23.
    • (2009) Statistics in Medicine , vol.28 , pp. 3-23
    • Alosh, M.1    Huque, M.F.2
  • 2
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework
    • Biomarkers Definitions Working Group (2001), “Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework,” Clinical Pharmacology and Therapeutics, 69, 89–95.
    • (2001) Clinical Pharmacology and Therapeutics , vol.69 , pp. 89-95
  • 4
    • 84949161149 scopus 로고
    • Stein's Estimation Rule and Its Competitors – An Empirical Bayes Approach
    • B.Efron,, and C.Morris, (1973), “Stein's Estimation Rule and Its Competitors – An Empirical Bayes Approach,” Journal of the American Statistical Association, 68, 117–130.
    • (1973) Journal of the American Statistical Association , vol.68 , pp. 117-130
    • Efron, B.1    Morris, C.2
  • 9
    • 84891747501 scopus 로고    scopus 로고
    • Roche Molecular Systems, Inc.
    • ——— (2012b), Summary of Safety and Effectiveness Data, Cobas 4800 BRAF V600 Mutation Test, Roche Molecular Systems, Inc. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=P110020
    • (2012) Cobas 4800 BRAF V600 Mutation Test
  • 10
    • 84902551498 scopus 로고    scopus 로고
    • Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff
    • ——— (2013a), Design Considerations for Pivotal Clinical Inves-tigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf
    • (2013) Design Considerations for Pivotal Clinical Inves-tigations for Medical Devices: Guidance for Industry
  • 11
    • 84925514576 scopus 로고    scopus 로고
    • ——— (2013b), Labeling Revision, Erbitux (cetuximab), Imclone Inc. available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125084s242lbl.pdf
    • (2013) Labeling Revision
  • 12
    • 84925514576 scopus 로고    scopus 로고
    • ——— (2013c), Labeling Revision, Ziagen (abacavir sulfate), ViiV Healthcare, available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020977s026,020978s030lbl.pdf
    • (2013) Labeling Revision
  • 14
    • 84925514575 scopus 로고    scopus 로고
    • Vectibix (panitumumab), Amgen Inc
    • ——— (2014b), Labeling Revision, Vectibix (panitumumab), Amgen Inc. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf
    • (2014) Labeling Revision
  • 15
    • 84925514575 scopus 로고    scopus 로고
    • Zelboraf (vemurafenib) Tablet, Hoffmann-La Roche Inc
    • ——— (2014c), Labeling Revision, Zelboraf (vemurafenib) Tablet, Hoffmann-La Roche Inc. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202429s006lbl.pdf
    • (2014) Labeling Revision
  • 18
    • 0022072706 scopus 로고
    • Testing for Qualitative Interaction Between Treatment Effects and Patient Subsets
    • M.Gail,, and R.Simon, (1985), “Testing for Qualitative Interaction Between Treatment Effects and Patient Subsets,” Biometrics, 41, 361–372.
    • (1985) Biometrics , vol.41 , pp. 361-372
    • Gail, M.1    Simon, R.2
  • 19
    • 52149112915 scopus 로고    scopus 로고
    • Pharmacogenetics of Hypersensitivity to Abacavir: From PGx Hypothesis to Confirmation to Clinical Utility
    • Mosteller, M., Warren, L. L., Lai, E. H., Brothers, C. H., Cox, C., Nelsen, A. J., Hughes, S., Thorborn, D. E., Stancil, B., Hetherington, S. V., Burns, D. K. and Roses, A. D.
    • A.R.Hughes,, W.R.Spreen,, Mosteller, M., Warren, L. L., Lai, E. H., Brothers, C. H., Cox, C., Nelsen, A. J., Hughes, S., Thorborn, D. E., Stancil, B., Hetherington, S. V., Burns, D. K. and Roses, A. D. (2008), “Pharmacogenetics of Hypersensitivity to Abacavir: From PGx Hypothesis to Confirmation to Clinical Utility,” Pharmacogenomics Journal, 8, 365–374.
    • (2008) Pharmacogenomics Journal , vol.8 , pp. 365-374
    • Hughes, A.R.1    Spreen, W.R.2
  • 21
    • 0141883593 scopus 로고    scopus 로고
    • Discussion of “P-Value Adjustments for Sub-Group Analyses,
    • G.G.Koch, (1997), Discussion of “P-Value Adjustments for Sub-Group Analyses,” Journal of Biopharmaceutical Statistics, 7, 323–331.
    • (1997) Journal of Biopharmaceutical Statistics , vol.7 , pp. 323-331
    • Koch, G.G.1
  • 22
    • 33846447795 scopus 로고    scopus 로고
    • The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homogenous Across All Subgroups
    • Z.Li,, C.Chuang-Stein,, and C.Hoseyni, (2007), “The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homogenous Across All Subgroups,” Drug Information Journal, 41, 47–56.
    • (2007) Drug Information Journal , vol.41 , pp. 47-56
    • Li, Z.1    Chuang-Stein, C.2    Hoseyni, C.3
  • 23
    • 0001015815 scopus 로고
    • Estimating a Population of Parameter Values using Bayes and Empirical Bayes Methods
    • T.A.Louis, (1984), “Estimating a Population of Parameter Values using Bayes and Empirical Bayes Methods,” Journal of the American Statistical Association, 79, 393–398.
    • (1984) Journal of the American Statistical Association , vol.79 , pp. 393-398
    • Louis, T.A.1
  • 24
    • 13644270099 scopus 로고    scopus 로고
    • On the Efficacy of Targeted Clinical Trials
    • A.Maitournam,, and R.Simon, (2005), “On the Efficacy of Targeted Clinical Trials,” Statistics in Medicine, 24, 329–339.
    • (2005) Statistics in Medicine , vol.24 , pp. 329-339
    • Maitournam, A.1    Simon, R.2
  • 26
    • 77953682084 scopus 로고    scopus 로고
    • Regional Differences in Multinational Clinical Trials: Anticipating Chance Variation
    • I.Marschner, (2010), “Regional Differences in Multinational Clinical Trials: Anticipating Chance Variation, Clinical Trials, 7, 147–156.
    • (2010) Clinical Trials , vol.7 , pp. 147-156
    • Marschner, I.1
  • 27
    • 84155164041 scopus 로고    scopus 로고
    • Efficacy and Safety of Once Daily Elvitegravir Versus Twice Daily Raltegravir in Treatment-Experienced Patients With HIV-1 Receiving a Ritonavir-Boosted Protease Inhibitor: Randomised, Double-Blind, Phase 3, Non-Inferiority Study
    • Clotet, B., Clumeck, N., Liu, Y. P., Zhong, L., Margot, N., Cheng, A. K., Chuck, S. L., for the Study 145 Team.
    • J.M.Molina,, A.LaMarca,, J.Andrade-Villanueva,, Clotet, B., Clumeck, N., Liu, Y. P., Zhong, L., Margot, N., Cheng, A. K., Chuck, S. L., for the Study 145 Team. (2012), “Efficacy and Safety of Once Daily Elvitegravir Versus Twice Daily Raltegravir in Treatment-Experienced Patients With HIV-1 Receiving a Ritonavir-Boosted Protease Inhibitor: Randomised, Double-Blind, Phase 3, Non-Inferiority Study,” Lancet Infectious Diseases, 12, 27–35.
    • (2012) Lancet Infectious Diseases , vol.12 , pp. 27-35
    • Molina, J.M.1    LaMarca, A.2    Andrade-Villanueva, J.3
  • 28
    • 84886915956 scopus 로고    scopus 로고
    • Analytical and Clinical Evaluation of Biomarkers Assays: When are Biomarkers Ready for Prime Time?
    • G.Pennello, (2013), “Analytical and Clinical Evaluation of Biomarkers Assays: When are Biomarkers Ready for Prime Time?” Clinical Trials, 10, 666–676.
    • (2013) Clinical Trials , vol.10 , pp. 666-676
    • Pennello, G.1
  • 29
    • 36248964740 scopus 로고    scopus 로고
    • A Note on Stratification in Clinical Trials
    • T.Permutt, (2007), “A Note on Stratification in Clinical Trials,” Drug Information Journal, 41, 719–722.
    • (2007) Drug Information Journal , vol.41 , pp. 719-722
    • Permutt, T.1
  • 30
    • 0031016256 scopus 로고    scopus 로고
    • Evaluating Treatment When a Gender by Treatment Interaction May Exist
    • E.Russek-Cohen,, and R.M.Simon, (1997), “Evaluating Treatment When a Gender by Treatment Interaction May Exist,” Statistics in Medicine, 16, 455–464.
    • (1997) Statistics in Medicine , vol.16 , pp. 455-464
    • Russek-Cohen, E.1    Simon, R.M.2
  • 32
    • 0037108041 scopus 로고    scopus 로고
    • Bayesian Subset Analysis: Application to Studying Treatment-by-Gender Interactions
    • R.Simon, (2002), “Bayesian Subset Analysis: Application to Studying Treatment-by-Gender Interactions,” Statistics in Medicine, 21, 2909–2916.
    • (2002) Statistics in Medicine , vol.21 , pp. 2909-2916
    • Simon, R.1
  • 33
    • 34547529442 scopus 로고    scopus 로고
    • A Method for Testing a Prespecified Subgroup in Clinical Trials
    • Y.Song,, and G.Y.Chi, (2007), “A Method for Testing a Prespecified Subgroup in Clinical Trials,” Statistics in Medicine, 26, 3535–3549.
    • (2007) Statistics in Medicine , vol.26 , pp. 3535-3549
    • Song, Y.1    Chi, G.Y.2
  • 34
    • 0141918127 scopus 로고    scopus 로고
    • The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. (2002), “Points to Consider on Multiplicity Issues in Clinical Trials London, UK,” available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf
    • (2002) Points to Consider on Multiplicity Issues in Clinical Trials London, UK
  • 35
  • 36
    • 79957438038 scopus 로고    scopus 로고
    • Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
    • Y.D.Zhao,, A.Dmitrienko, and R.Tamura, (2010), “Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation,” Statistics in Biopharmaceutical Research, 2, 72–83.
    • (2010) Statistics in Biopharmaceutical Research , vol.2 , pp. 72-83
    • Zhao, Y.D.1    Dmitrienko, A.2    Tamura, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.